で公開中です! 詳しく見る
CYTKのアイコン

Cytokinetics

61.95 USD
-1.97
3.08%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
62.10
+0.15
0.24%
1日
-3.08%
5日間
-0.85%
1か月
-10.72%
3か月
-22.91%
6か月
-5.3%
年初来
0.36%
1年
5.07%
5年間
73.19%
10年間
581.52%
 

概要: Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

従業員数: 673

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 31.3%
ニュートラル 65.6%
ネガティブ 3.1%
ニュートラル
GlobeNewsWire
4 日前
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
ニュートラル
GlobeNewsWire
14 日前
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
ニュートラル
GlobeNewsWire
16 日前
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
ポジティブ
MarketBeat
21 日前
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure.
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
ニュートラル
GlobeNewsWire
29 日前
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 shares of common stock and 35,025 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 23 employees, whose employment commenced in August and September 2026 as a material inducement to their employment.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ニュートラル
Seeking Alpha
先月
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ネガティブ
Seeking Alpha
先月
Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet
Cytokinetics, Incorporated's stock remains under pressure. At the same time, Myqorzo sales rose 427.1% quarter-over-quarter to $25.3 million in the second quarter, despite competitive pressure from Bristol Myers Squibb's Camzyos. Meanwhile, the August 28 NEJM article revealed full Phase 3 ACACIA-HCM data, in which Myqorzo showed high efficacy in treating symptomatic nonobstructive HCM, where Camzyos failed.
Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet
ニュートラル
GlobeNewsWire
先月
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
ニュートラル
Seeking Alpha
先月
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
ニュートラル
GlobeNewsWire
先月
Cytokinetics to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi 2026 BioPharma Back to School Conference: Fireside chat on Wednesday, September 9, 2026 at 3:00 PM Eastern Time in New York, NY.
Cytokinetics to Participate in September Investor Conferences
価格チャートは Lightweight Charts™ を使用して実装されています